Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04314544 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
A Phase 3 study of Active Psoriatic Arthritis, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 508
- Enrollment target
- 20
- Study locations
NCT04314544 is a Phase 3 study of Active Psoriatic Arthritis that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 508 participants, above the 252-participant average among 3 other Active Psoriatic Arthritis trials with a reported enrollment target (102% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT04314544, a Phase 3 study of Active Psoriatic Arthritis, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 508 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
Conditions Studied
Interventions
- DRUG TILD
- DRUG matching placebo injections
Study Locations (20)
Florida
- Sunpharma Site no. 141 - Avon Park
- Sunpharma site no. 21 - Clearwater
- Sunpharma site no. 02 - Hialeah
- Sunpharma Site no 55 - Kissimmee
- Sunpharma Site no. 75 - Margate
- Sunpharma site no. 05 - New Port Richey
- Sunpharma Site no. 76 - Ocoee
- SunPharma Site no 22 - Tamarac
California
- Sunpharma Site no 35 - Covina
- Sunpharma Site no 48 - Encino
- Sunpharma site no. 17 - Fountain Valley
- Sunpharma site no. 15 - Thousand Oaks
Arizona
- Sunpharma Site no 29 - Gilbert
- Sunpharma Site no 30 - Glendale
- Sunpharma Site no 31 - Mesa
Illinois
- Sunpharma Site no 41 - Oak Brook
- Sunpharma Site no 54 - Orland Park
- Sunpharma Site no 38 - Schaumburg
Alabama
- Sunpharma Site no 42 - Dothan
Georgia
- Sunpharma Site no 46 - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2025-12-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04314544
The ClinicalTrials.gov registry entry for NCT04314544 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 508 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 252-participant average among 3 other Active Psoriatic Arthritis trials with a reported enrollment target (102% higher). The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Active Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which TILD is the first listed.
NCT04314544 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT04314544 about?
NCT04314544 is a clinical study titled "Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)". This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
What is the current status of trial NCT04314544?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 508 participants. The study started on 2020-07-01. Estimated completion is 2025-12-22.
What conditions does trial NCT04314544 study?
This clinical trial studies the following conditions: Active Psoriatic Arthritis.
What interventions are being tested in trial NCT04314544?
The interventions under investigation include: TILD (DRUG), matching placebo injections (DRUG).
Who is sponsoring clinical trial NCT04314544?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04314544 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Active Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
COMPLETED · Phase 3
-
Efficacy and Safety Study of SUNPG1623
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.